PureTech Health PLC Net Assets
PureTech Health PLC net assets. Based on the latest financial reports, PureTech Health PLC (PRTC) has net assets worth $305.68 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($534.71 Million) and total liabilities ($229.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is PureTech Health PLC growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $305.68 Million |
| % of Total Assets | 57.17% |
| Annual Growth Rate | N/A |
| 5-Year Change | -47.67% |
| 10-Year Change | 230.78% |
| Growth Volatility | 97.4 |
Net Assets of PureTech Health PLC (2012–2025)
Net assets of PureTech Health PLC from 2012 to 2025. This chart illustrates how PureTech Health PLC's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of PureTech Health PLC to measure how much of total assets are equity-financed.
Annual Net Assets for PureTech Health PLC (2012–2025)
The table below shows the annual net assets of PureTech Health PLC from 2012 to 2025. For live market cap and overall valuation, see market value of PureTech Health PLC.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $305.68 Million | -25.07% |
| 2024-12-31 | $407.93 Million | -10.98% |
| 2023-12-31 | $458.23 Million | -16.32% |
| 2022-12-31 | $547.59 Million | -6.26% |
| 2021-12-31 | $584.15 Million | -10.62% |
| 2020-12-31 | $653.54 Million | +0.48% |
| 2019-12-31 | $650.40 Million | +289.53% |
| 2018-12-31 | $166.97 Million | +160.91% |
| 2017-12-31 | $64.00 Million | -30.75% |
| 2016-12-31 | $92.41 Million | -43.67% |
| 2015-12-31 | $164.05 Million | +22.71% |
| 2014-12-31 | $133.69 Million | +1765.47% |
| 2013-12-31 | $-8.03 Million | -139.33% |
| 2012-12-31 | $-3.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PureTech Health PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 9217200000.0% over the analyzed period, indicating profitable operations and earnings retention.
PureTech Health PLC Net Assets Breakdown (December 2025)
PureTech Health PLC net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $61.27 Million | 19.63% |
| Common Stock | $4.86 Million | 1.56% |
| Other Comprehensive Income | $182.00K | 0.06% |
| Other Components | $245.76 Million | 78.75% |
| Total Equity | $312.07 Million | 100.00% |
PureTech Health PLC Competitors by Market Cap
The table below lists competitors of PureTech Health PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Huachen Transformer
SHG:603097
|
$423.17 Million |
|
Zinzino AB Series B
ST:ZZ-B
|
$423.26 Million |
|
Dalmia Bharat Sugar and Industries Limited
NSE:DALMIASUG
|
$423.26 Million |
|
Liaoning Fu-An
SHG:603315
|
$423.32 Million |
|
Shanghai Titan Scientific Co. Ltd. A
SHG:688133
|
$422.77 Million |
|
InBody Co.Ltd
KQ:041830
|
$422.58 Million |
|
Star Gas Partners LP
NYSE:SGU
|
$422.57 Million |
|
Norma Group AG NA O.N.
XETRA:NOEJ
|
$422.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PureTech Health PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 414,707,000 to 312,073,000, a change of -102,634,000 (-24.7%).
- Net loss of 109,739,000 reduced equity.
- Share repurchases of 2,057,797 reduced equity.
- New share issuances of 106,000 increased equity.
- Other comprehensive income decreased equity by 133,781,000.
- Other factors increased equity by 142,837,797.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-109.74 Million | -35.16% |
| Share Repurchases | $2.06 Million | -0.66% |
| Share Issuances | $106.00K | +0.03% |
| Other Comprehensive Income | $-133.78 Million | -42.87% |
| Other Changes | $142.84 Million | +45.77% |
| Total Change | $- | -24.75% |
Book Value vs Market Value Analysis
This analysis compares PureTech Health PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.13x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 35.60x to 0.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.49 | $17.38 | x |
| 2013-12-31 | $-0.14 | $17.38 | x |
| 2014-12-31 | $21.71 | $17.38 | x |
| 2015-12-31 | $12.20 | $17.38 | x |
| 2016-12-31 | $7.74 | $17.38 | x |
| 2017-12-31 | $8.97 | $17.38 | x |
| 2018-12-31 | $10.06 | $17.38 | x |
| 2019-12-31 | $22.90 | $17.38 | x |
| 2020-12-31 | $22.87 | $17.38 | x |
| 2021-12-31 | $20.71 | $17.38 | x |
| 2022-12-31 | $19.04 | $17.38 | x |
| 2023-12-31 | $16.80 | $17.38 | x |
| 2024-12-31 | $15.38 | $17.38 | x |
| 2025-12-31 | $129.61 | $17.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PureTech Health PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2355.42%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.71x
- Recent ROE (-35.16%) is below the historical average (-29.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -357.27% | -139.36% | 0.41x | 6.20x | $-11.36 Million |
| 2013 | 0.00% | -61.31% | 0.42x | 0.00x | $-4.21 Million |
| 2014 | -23.26% | -2069.73% | 0.01x | 1.27x | $-59.54 Million |
| 2015 | -17.42% | -335.55% | 0.04x | 1.45x | $-62.01 Million |
| 2016 | -27.46% | -1101.15% | 0.01x | 1.68x | $-66.56 Million |
| 2017 | 14.40% | 4749.08% | 0.00x | 1.59x | $9.44 Million |
| 2018 | -15.84% | -266.65% | 0.04x | 1.60x | $-71.20 Million |
| 2019 | 63.04% | 4847.42% | 0.01x | 1.41x | $354.34 Million |
| 2020 | 0.89% | 71.75% | 0.01x | 1.48x | $-60.99 Million |
| 2021 | -10.20% | -606.85% | 0.01x | 1.59x | $-119.91 Million |
| 2022 | -9.29% | -2409.33% | 0.00x | 1.30x | $-104.58 Million |
| 2023 | -14.16% | -1972.88% | 0.00x | 1.50x | $-112.10 Million |
| 2024 | 12.90% | 1108.33% | 0.01x | 1.45x | $12.04 Million |
| 2025 | -35.16% | -2355.42% | 0.01x | 1.71x | $-140.95 Million |
Industry Comparison
This section compares PureTech Health PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $211,904,180
- Average return on equity (ROE) among peers: 1119.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PureTech Health PLC (PRTC) | $305.68 Million | -357.27% | 0.75x | $423.06 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $27.43 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $178.43 Million | -42.75% | 0.25x | $241.32 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $15.62 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $155.53K | 11625.26% | 37.80x | $804.31 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.70 Billion |
About PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The co… Read more